Huda Salman

Dr. Huda Salman

Brown Center for Immunotherapy, Indiana University, Indianapolis, IN 46202, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
HSHuda Salman
Huda Salman
KPKevin G. Pinz
Kevin G. Pinz
MWMasayuki Wada
Masayuki Wada
XSXiao Shuai
Xiao Shuai
LYLulu E. Yan
Lulu E. Yan
YMYupo Ma
Yupo Ma
Acute myeloid leukemia (AML) is an aggressive malignancy lacking targeted therapy due to shared molecular and transcriptional circuits as well as phenotypic markers with normal hematopoietic stem cells (HSCs). Identifying leukemia specific markers expressed on AML or AML subtypes for therapeutic targeting is of exquisite clinical value. Here we show that CD4, a T lymphocytes membrane glycoprotein that interacts with major histocompatibility complex class II antigens and is also expressed in certain AML subsets but not on HSCs is a proper target for genetically engineered chimeric antigen receptor T cells (CAR-T cells). Treatment with CD4 redirected CAR-T cell (CD4CAR) specifically eliminated CD4-expressing AML cell lines in vitro and exhibited a potent anti-leukemic effect in a systemic AML murine model in vivo. We also utilized natural killers as another vehicle for CAR engineered cells and this strategy similarly and robustly eliminated CD4- expressing AML cells in vitro and had a potent in vivo anti-leukemic effect and was noted to have shorter in vivo persistence. Our data offer a proof of concept for immunotherapeutic targeting of CD4 as a strategy to treat CD4 expressing refractory AML as a bridge to stem cell transplant (SCT) in a first in human clinical trial.

2 April 2025 in Molecular Therapy
Verified
Journal Article
Open access
MKMalak Khalifeh
Malak Khalifeh
EHEmily Hopewell
Emily Hopewell
HSHuda Salman
Huda Salman
Despite recent U.S. FDA approval of multiple therapies for patients with acute myeloid leukemia (AML), clinical outcomes for those patients continue to remain poor. There are very few effective immunotherapeutic modalities such as allogeneic stem cell transplant, SCT, for AML, and this is, in part, due to a lack of known antigens which are unique to AML and not present on vital normal hematopoietic precursors. Additionally, AML is supported by a hostile marrow TME that has a notable role in dampening T cell effector function 1-4. MDSCs and Tregs play a pivotal role in AML microenvironment immune hostility towards endogenous T cells as well as adoptively transferred T cells (ACT). There are many clinical trials that are designed to test the feasibility and efficacy of ACT including Chimeric Antigen Receptor T cell therapies (CAR T cell) in AML, yet none is FDA approved for this fatal disease. In this review, we dissect these trials, their contribution to this therapeutic direction and their success.

25 January 2025 in Molecular Therapy
Verified
Journal Article
Open access
MKMalak Khalifeh
Malak Khalifeh
HSHuda Salman
Huda Salman
Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment and is now being explored for other diseases, such as autoimmune disorders. While the tumor microenvironment (TME) in cancer is often immunosuppressive, in autoimmune diseases, the environment is typically inflammatory. Both environments can negatively impact CAR T cell survival: the former through direct suppression, hypoxia, and nutrient deprivation, and the latter through chronic T cell receptor (TCR) engagement, risking exhaustion. Mechanisms of resistance include T cell exhaustion, dysfunction, and the impact of the TME. Chronic antigenic stimulation leads to CAR T cell exhaustion. CAR construct design, including co-stimulatory domains, hinge, transmembrane regions, promoters, the affinity of the binder site and on /off rate plays a crucial role in modulating CAR T cell function and resistance. This review discusses the impact of the in vitro development of CAR T cells, albeit in relation to the TME, on therapeutic outcomes. The use of alternative cell sources, multi-antigen targeting, and re-engineering the TME, are discussed. The review emphasizes the need for continued innovation in CAR T cell design and manufacturing to optimize therapeutic efficacy and durability, especially in the face of varying environmental challenges.

15 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
HSHuda Salman
Huda Salman
XSXiao Shuai
Xiao Shuai
ANAnh Thu Nguyen-Lefebvre
Anh Thu Nguyen-Lefebvre
BGBanabihari Giri
Banabihari Giri
MRMingqiang Ren
Mingqiang Ren
YMYupo Ma
Yupo Ma
SALL1 expression in acute myeloid leukemia SALL1 expression in acute myeloid leukemia

22 September 2021 in Cells
Verified
Journal Article
Open access
PDF file
Yasharah RazaYasharah Raza
Yasharah Raza
HSHuda Salman
Huda Salman
CLChiara Luberto
Chiara Luberto
Sphingolipids, associated enzymes, and the sphingolipid pathway are implicated in complex, multifaceted roles impacting several cell functions, such as cellular homeostasis, apoptosis, cell differentiation, and more through intrinsic and autocrine/paracrine mechanisms. Given this broad range of functions, it comes as no surprise that a large body of evidence points to important functions of sphingolipids in hematopoiesis. As the understanding of the processes that regulate hematopoiesis and of the specific characteristics that define each type of hematopoietic cells is being continuously refined, the understanding of the roles of sphingolipid metabolism in hematopoietic lineage commitment is also evolving. Recent findings indicate that sphingolipid alterations can modulate lineage commitment from stem cells all the way to megakaryocytic, erythroid, myeloid, and lymphoid cells. For instance, recent evidence points to the ability of de novo sphingolipids to regulate the stemness of hematopoietic stem cells while a substantial body of literature implicates various sphingolipids in specialized terminal differentiation, such as thrombopoiesis. This review provides a comprehensive discussion focused on the mechanisms that link sphingolipids to the commitment of hematopoietic cells to the different lineages, also highlighting yet to be resolved questions.

1 January 2018 in Leukemia Research Reports
Verified
Journal Article
Open access
GMGina Ma
Gina Ma
YWYi Wang
Yi Wang
TATahmeena Ahmed
Tahmeena Ahmed
AZAnn-Leslie Zaslav
Ann-Leslie Zaslav
LHLaura Hogan
Laura Hogan
HSHuda Salman
Huda Salman
Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.